Today, 70% of African asthma and COPD sufferers are undiagnosed and the WHO forecasts a 20% increase in respiratory related deaths in the next 10 years. AstraZeneca asked us to create awareness and ...
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...
AstraZeneca (AZ) and its biologics R&D arm, MedImmune, have announced that the latest respiratory trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive ...
AstraZeneca is to pay up to $225 million to develop and market a respiratory drug which could help restore its position in the therapy area. The company has a heritage in respiratory drugs ...
For over five decades, AstraZeneca has been at the forefront of serving respiratory patients through substantial investments ...
AstraZeneca has completed its clinical programme supporting the transition of its respiratory medicine to a low-carbon propellant with considerably lower Global Warming Potential (GWP).
(Bloomberg) -- AstraZeneca Plc agreed to buy Icosavax Inc. for as much as $1.1 billion to gain a developer of innovative vaccines for respiratory viruses. Astra offered $15 in cash for each of ...
As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making preparations to avoid last year's supply issue with a newly approved filling l ...
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
Paid and presented by AstraZeneca. When Cleusa was diagnosed with advanced lung cancer, she needed support attending her appointments in the city. Find out how a respiratory programme is helping ...
After more than three billion doses, the Oxford-AstraZeneca Covid vaccine is being withdrawn. AstraZeneca said it was "incredibly proud" of the vaccine, but it had made a commercial decision.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...